NCT05490771View on ClinicalTrials.gov

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

January 6, 2021

Study Completion Date

December 31, 2025

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Copanlisib Hydrochloride

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT05490771 - Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | Biotech Hunter | Biotech Hunter